Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5/pos/1.html?cHash=f5f2e5fdbfbf799a701ac9c5e77ce04b&sort=desc

Kurszettel

Alle Kurse

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.21 EUR3.69%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR263.3%
  • SYNGENTA422.00 CHF29.1%
  • WILEX4.21 EUR23.8%

FLOP

  • CYTOS0.63 CHF-42.7%
  • MEDIGENE8.58 EUR-32.4%
  • BIOTEST76.00 EUR-22.8%

TOP

  • WILEX4.21 EUR419.8%
  • CYTOS0.63 CHF350.0%
  • 4SC4.65 EUR322.7%

FLOP

  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.89 EUR-21.3%

No liability assumed, Date: 22.05.2015